Oncotelic Therapeutics Inc. OTLC Archives - Page 2 of 3

TuesdayNov 11, 2025 10:45 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of their review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; https://doi.org/10.3390/ijms262210842). Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the paper is the first to comprehensively examine nanoparticles exclusively within the 5–15 nm range—an emerging scale poised to redefine nanomedicine. The review highlights how these sub-15 nm systems achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across…

FridayNov 07, 2025 3:25 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited,” said Dr. Sud Agarwal, CEO of Ingenu, a contract research organization in Australia. “We are proud…

MondayNov 03, 2025 12:00 pm

Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium

The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003. The announcement occurred at the Australian…

FridayOct 31, 2025 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that Sapu Nano’s investigational intravenous Deciparticle(TM) everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, Dec. 9–12, 2025, in San Antonio, Texas. Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 is a novel Deciparticle(TM) formulation of everolimus designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, RCC, and NET. To view the full press release, visit https://ibn.fm/bCNnk About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

ThursdayOct 23, 2025 11:35 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. Developed by Sapu Nano—a joint venture between Oncotelic and Dragon Oversea—Sapu003 is a novel IV formulation of everolimus designed to overcome the limitations of oral mTOR inhibitors such as Afinitor (R), including poor bioavailability and restricted tumor penetration. The abstracts collectively detail the clinical rationale, molecular biomarkers,…

TuesdayOct 21, 2025 9:00 am

Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

Sapu003 Phase 1 trial begins: Australian HREC approval validates Oncotelic’s proprietary 20nm nanoparticle technology for enhanced breast cancer drug delivery 20nm Deciparticle(TM) achieves full bioavailability: Intravenous delivery of Everolimus (Afinitor(R)) maximizes tumor targeting and efficacy compared to 10% absorption with oral formulations Rapid IND platform accelerates pipeline: Strategic partnership with Medicilon supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle(TM) drug candidates to reach clinical testing quickly Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing…

FridayOct 17, 2025 2:18 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and individualized vaccines. Yet despite this progress, significant unmet needs persist, particularly in rare pediatric cancers, resistant solid tumors and underserved population. Oncotelic is strategically positioned to fill gaps where traditional treatments fall short,” the article reads.…

WednesdayOct 08, 2025 10:30 am

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients Oncotelic Therapeutics (OTCQB: OTLC) is…

WednesdayOct 01, 2025 11:15 am

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003 Sapu003 uses Sapu Nano’s Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic…

WednesdaySep 24, 2025 9:40 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer

Oncotelic Therapeutics (OTCQB: OTLC) announced that its joint venture through GMP Biotechnology Limited, Sapu Nano, has received approval from Australia’s Human Research Ethics Committee to begin enrolling patients in a Phase 1 human clinical trial of Sapu003, an injectable form of Everolimus for breast cancer. Everolimus, marketed as Afinitor(R), is FDA-approved in oral form but has limited absorption of about 10%. Using Sapu Nano’s Deciparticle(TM) technology, Sapu003 is delivered intravenously, allowing full drug absorption into the bloodstream. Preclinical data suggest this approach could improve efficacy over the oral version. The trial will determine optimal dosing for future studies, including a…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC